Apomorphine in Parkinson's Disease Patients With Visual Hallucinations

Inclusion Criteria: * Female and male subjects aged ≥30; * Diagnosis of established PD, defined by the Movement Disorders Society PD criteria (Postuma et al., 2015); * Presence of visual severe hallucinations defined as more than 3 times a week (van Laar et al., 2010); * Visual hallucinations must have developed after PD diagnosis; * Visual hallucinations must have been optimally treated with reduction of dopamine agonists if possible, and prescription of clozapine and/or cholinesterase inhibitors if needed; * Female subjects must complaint with a highly effective contraceptive method (oral hormonal contraception alone is not considered highly effective and must be used in combination with a barrier method) during the study, if sexually active; * Subjects should be able and capable of adhering to the protocol, visit schedules, and medication intake according to the judgement of the investigator. Exclusion Criteria: * Symptomatic, clinically relevant and medically uncontrolled orthostatic hypotension; * Patients with a prolonged QT interval corrected for heart rate according to Bazett's formula (QTc) of \>450 ms for male and \>470 ms for female at screening, or history of a long QT syndrome; * PD medication change (i.e., dopamine-agonists, amantadine, monoamine oxidase (MAO)-B inhibitors, anticholinergics and cholinesterase inhibitors) in last month prior to initiation (van Laar et al., 2010); * Active psychosis or a history of significant psychosis; * Any medical condition that is likely to interfere with an adequate participation in the study including e.g. current diagnosis of unstable epilepsy, clinically relevant cardiac dysfunction and/or myocardial infarction or stroke within the last 12 months.